


CLAIMS


1. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis consist of the combination of a compound represented by the following general formula (I) or pharmaceutical acceptable salts and cholesterol biosynthesis inhibitors and/or fibrate-type cholesterol lowering agents,



wherein A₁, A₃ and A₄ are hydrogen atom, halogen atom, alkyl group having one to five carbon atoms, alkoxy group having one to five carbon atoms, -COOR₁, a group represented by following formula (b)



wherein R₁ is hydrogen atom or alkyl group having one to five carbon atoms, or a group represented by following formula (a)




wherein R₂ is -CH₂OH group, -CH₂OC(O)-R₁ group or -CO₂-R₁ group; R₃ is -OH group or -OC(O)-R₁ group; R₄ is -(CH₂)_kR₅(CH₂)_l-, wherein k and l are an integer of


0 or more than 1; k + l is 10 or fewer integer, and R₄ group binds to tetrahydropyran ring by C-C bond, further, R₅ means single bond (-), -CH=CH-, -OCH₂-, carbonyl group or -CH(OH)-,

and more than one of A₁, A₃ and A₄ in formula (I) must be the group in above-mentioned formula (a), A₂ is alkyl chain having one to five carbon atoms, alkoxy chain having one to five carbon atoms, alkenyl chain having one to five carbon atoms, hydroxyl alkyl chain having one to five carbon atoms or carbonyl alkyl chain having one to five carbon atoms. n, p, q or r are 0, 1 or 2.

2. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis describe in claim 1 consist of the mixture of a compound represented by the above general formula (I) or pharmaceutical acceptable salts and cholesterol biosynthesis inhibitors and/or fibrate-type cholesterol lowering agents.
3. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis formed a kit by single packaging a container containing a compound represented by the above general formula (I) or pharmaceutical acceptable salts and a container containing cholesterol biosynthesis inhibitor and/or fibrate-type cholesterol lowering agents.
4. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to anyone of claims 1, 2 and 3 consist of a compound which the above-mentioned general formula (I) is the following formula.



5. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to anyone of claims 1, 2 and 3 consist of a compound which the above-mentioned general formula (I) is the following formula.



6. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to anyone of claims 1-5 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxidase inhibitors.

7. Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to anyone of claims 1-5 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.
8. A dosage method of serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis characterized by the administration of a compound represented by the above-mentioned formula (I) or pharmaceutical acceptable salts and cholesterol biosynthesis inhibitors and/or fibrate-type cholesterol lowering agents simultaneously or consecutively.